# Muse cell therapy

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Therapy
Updated: 2026-10-15
Canonical: https://heretic.bio/articles/muse-cell-therapy-evidence-taxonomy-and-clinical-translation.html

> Muse cells are stress-enduring, pluripotent-like cells discovered by Mari Dezawa's group, infused without HLA matching. Small academic Japanese trials report improved heart function after heart attack, faster ulcer healing in epidermolysis bullosa, and a roughly 40% responder rate in subacute stroke versus 10% on placebo. The anti-aging claims marketed by Eterna Health rest on a two-patient case series measured by an epigenetic clock. No large randomized trial exists for any indication.

## Overview

Muse Cell Therapy (Medical Use of Stretch-activated Natural Cytoplasts) is being marketed by Eterna Health (Dr. Adeel Khan) for longevity, anti-aging, and tissue repair. Zac Efron has been publicly documented as a patient. Muse cells are proposed pluripotent-like cells distinct from conventional MSCs.

## Evidence Taxonomy

**In-Vitro:** \- Muse cells (Multi-lineage differentiating Stress Enduring cells) demonstrate pluripotency markers (SSEA-3, Tra-1-81) and tri-lineage differentiation potential under stress conditions; discovered by Dr. Mari Dezawa (Tohoku University). \- Homing via sphingosine-1-phosphate (S1P/S1PR2) bystander signaling documented in cell culture; superior migratory capacity vs conventional MSCs. \- Low immunogenicity: HLA-mismatched donor cells survive without immunosuppression in vitro and in vivo (key differentiator).

**Animal Models:** \- Rodent stroke model: IV Muse cells improved functional recovery (Fugl-Meyer, corner-turn tests) vs MSC controls. \- Rodent acute MI model: Improved left ventricular ejection fraction (LVEF); durable engraftment without immunosuppressants. \- Spinal cord injury and epidermolysis bullosa models: Accelerated tissue repair.

**Early Human Evidence (2024–2026):** \- **Japanese CL2020 donor Muse cell trials** (academic, peer-reviewed): \- Acute MI: Improved LVEF on cardiac MRI. \- Epidermolysis bullosa (EB): Accelerated ulcer healing. \- Subacute ischemic stroke: Phase I/II — Fugl-Meyer Motor Scale responder rate ~40% vs ~10% placebo (small n). \- ALS: ALSFRS-R stabilization trend. \- All intravenous, without HLA matching. \- **Eterna Health (Dr. Adeel Khan, 2025):** Case series (n=2) published showing multi-system biological age reversal measured by SystemAge epigenetic clock post IV Muse cell therapy. First claimed "published clinical evidence of age reversal." Clinic operates in Mexico/Canada. \- **Limitations:** No large Phase II/III RCTs for longevity/anti-aging indications as of July 2026; mostly small case series or Japanese academic trials in specific disease indications (stroke, AMI, EB, ALS). \- **Regulatory:** Experimental in US/Canada; not FDA-approved for anti-aging/longevity; offered via medical tourism in Mexico. Ongoing observational safety study.

## Differentiation from MSCs

Muse cells purportedly home more specifically to damage sites and exert effects through paracrine signaling without requiring engraftment. Distinct isolation method (stress-activated).

## Key Players & Claims Audit

  * **Eterna Health (Dr. Adeel Khan):** Longevity Med Summit presentations; claims broad regenerative applications.
  * **Exposed Risks:** Limited independent replication; clinic-level evidence only.
  * **Zac Efron Documentation:** Public mentions but no peer-reviewed outcomes.



## Regulatory & Competitive Landscape

  * US FDA: Not approved for anti-aging/longevity indications.
  * Competitive: Overlaps with MSC/exosome therapies (see 15-Exosome-Therapy/Exosome Therapy).
  * Positioning: Experimental regenerative; emphasize research-stage for clinics.



## Recommended Sections for Expansion

  * Full protocol details (if available from sources)
  * Safety signals from clinic data
  * Comparison table: Muse vs MSC vs Exosomes



## Primary-source focus. Early human evidence only. No medical advice.

_Expanded with evidence tiers and regulatory context._

## Sources